生物活性

• 描述AMG-131 is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00952445	Diabetes Mellitus, Type II	Phase 2	Completed	-	United States, California ... more >> Whittier Diabetes Institute La Jolla, California, United States Charles R. Drew University Los Angeles, California, United States National Research Institute Los Angeles, California, United States Lovelace Research Institute Santa Ana, California, United States United States, Florida University of Miami Miami, Florida, United States United States, Indiana GFI Research Center Evansville, Indiana, United States United States, Massachusetts Joslin Diabetes Center Boston, Massachusetts, United States United States, Minnesota Radiant Research Edina, Minnesota, United States United States, Missouri Radiant Research St. Louis, Missouri, United States St Louis Center for Clinical Research St. Louis, Missouri, United States United States, New York Kaleida Health Diabetes Center Buffalo, New York, United States Rochester Clinical Research Rochester, New York, United States United States, North Carolina Duke University Medical Center Durham, North Carolina, United States United States, Oregon Radiant Research Portland, Oregon, United States United States, South Carolina Radiant Research Anderson, South Carolina, United States United States, Texas Baylor University Endocrine Center Dallas, Texas, United States Dallas Diabetes and Endocrine Research Center Dallas, Texas, United States Endocrine Associates of Dallas Dallas, Texas, United States Diabetes and Grandular Disease Clinic and Reseach Center San Antonio, Texas, United States United States, Utah Endocrine Research Specialists Ogden, Utah, United States United States, Virginia Salem VA Medical Center Salem, Virginia, United States Collapse <<
  NCT02638038	Multiple Sclerosis, Relapsing ... more >>Remitting Collapse <<	Phase 2	Completed	-	-
  NCT00631007	-	-	Completed	-	-

• 更多
• 参考文献

• [1] Taygerly JP, McGee LR, et al. Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity. Bioorg Med Chem. 2013 Feb 15;21(4):979-92.

  [2] Lee DH, Huang H, et al. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2012 Mar 1;302(5):E552-60.